Results 51 to 60 of about 20,461 (225)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

The role of machine learning in the modern management of heart failure

Cardiologia Hungarica
Introduction: The use of machine learning is exploding in all areas of healthcare, including the diagnosis and treatment of heart failure. Supervised machine learning can help predict the onset of heart failure, establish the diagnosis, and even predict ...
Gáspár Dániel, Komlósi Ferenc, Bohus Gyula, Tóth Patrik, Sax Balázs, Heltai Krisztina, Vándor László, Becker Dávid, Merkely Béla, Nagy Klaudia Vivien   +9 more
doaj   +1 more source

Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. [PDF]

PLoS ONE, 2016
Biomarker discovery and new insights into the pathophysiology of heart failure with reduced ejection fraction (HFrEF) may emerge from recent advances in high-throughput urinary proteomics.
Kasper Rossing, Helle Skovmand Bosselmann, Finn Gustafsson, Zhen-Yu Zhang, Yu-Mei Gu, Tatiana Kuznetsova, Esther Nkuipou-Kenfack, Harald Mischak, Jan A Staessen, Thomas Koeck, Morten Schou   +10 more
doaj   +1 more source

The evolving role of adiponectin as an additive biomarker in HFrEF [PDF]

Heart Failure Reviews, 2016
Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF.
Sente, Tahnee, Gevaert, Andreas, van Berendoncks, An, Vrints, Christiaan J., Hoymans, Vicky Y.   +4 more
openaire   +2 more sources

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Correlation of NT-proBNP Levels with Outcome in Patients of Acute Decompensated Heart Failure

Indian Journal of Medical Specialities
Background: Acute decompensated heart failure (ADHF) is a significant contributor to morbidity and mortality globally, particularly in resource-limited settings like India.
Dheeraj Balotia, Anshuman Srivastava, Amitesh Aggarwal, Alpana Raizada, Rahul Sharma   +4 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients

BMC Nephrology, 2020
Background Peritoneal ultrafiltration (pUF) in refractory heart failure (HF) reduces the incidence of decompensation episodes, which is of particular significance as each episode incrementally adds to mortality.
Leonie Grossekettler, Bastian Schmack, Carsten Brockmann, Reinhard Wanninger, Michael M. Kreusser, Lutz Frankenstein, Lars P. Kihm, Martin Zeier, Hugo A. Katus, Vedat Schwenger, Andrew Remppis   +10 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source